WVE · Wave Life Sciences, Inc.
$3.18
-5.08% last session
End-of-day data · close of 2026-10-23
Market cap
$1B
Enterprise value
<$1M
Trailing P/E
—
Forward P/E
-2.7
Dividend yield
0.0%
Beta
-1.43
Avg volume
3M
Employees
0K
Daily Change %
-5.08%
5 Days Change
7.03%
10 Days Change
6.69%
30 Days Change
-15.19%
60 Days Change
-34.57%
Month to Day Change
-13.66%
Year to Day Change
-80.29%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — WVE
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-10-16
Latest call per bank · past 12 months
UBS
Buy$11.00
+245.9% vs priceJP Morgan
Neutral$0.00
-100.0% vs priceCitigroup
Buy$19.00
+497.5% vs priceWells Fargo
Overweight$14.00
+340.3% vs priceBank of America
Buy$21.00
+560.4% vs priceRBC Capital
Outperform$27.00
+749.1% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-16 | William Blair | Initiates | Outperform | $0.00 |
| 2026-10-15 | UBS | Initiates | Buy | $0.00 → $11.00 |
| 2026-10-01 | Ladenburg Thalmann | Initiates | Buy | $0.00 → $10.00 |
| 2026-09-23 | JP Morgan | Downgrade | Overweight → Neutral | $0.00 |
| 2026-08-04 | Mizuho | Maintains | Outperform | $27.00 → $23.00 |
| 2026-07-31 | Citigroup | Maintains | Buy | $24.00 → $19.00 |
| 2026-07-31 | B. Riley Securities | Maintains | Buy | $31.00 → $22.00 |
| 2026-07-31 | Wedbush | Maintains | Outperform | $15.00 → $12.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-10-23
- neutral: RSI (14): RSI is 32 — neutral momentum, neither overbought nor oversold.
- bearish: Price vs 50-day MA: Trading 25.0% below the 50-day MA ($4.24).
- bearish: Price vs 200-day MA: Trading 58.6% below the 200-day MA ($7.69).
- bearish: MA cross: The 50-day MA sits below the 200-day MA (death-cross regime) — the longer-term trend points down.
- bullish: MACD (12,26,9): MACD histogram is positive (+0.05) — short-term momentum is improving.
- bearish: 52-week range: Price is within 10% of the 52-week low ($3.09).
WVE Price Chart
Loading chart for WVE…
Fundamentals
About Wave Life Sciences, Inc.
Wave Life Sciences, Inc., a clinical-stage biotechnology company, focuses on unlocking the potential of ribonucleic acid (RNA) medicines to transform human health. Its RNA medicines platform, PRISM, combines RNA medicine modalities, chemistry innovation, and deep insights in human genetics to deliver scientific breakthroughs that treat rare and common disorders. Its pipeline focuses on obesity (WVE-007), alpha-1 antitrypsin deficiency (AATD) (WVE-006), and PNPLA3 I148M liver disease (WVE-008) programs; and clinical programs for Duchenne muscular dystrophy and Huntington's disease, as well as various preclinical programs utilizing its RNA medicines platform. Wave Life Sciences, Inc. was founded in 2012 and is headquartered in Cambridge, Massachusetts.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$133B 18.1% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$83B 6.5% YTD
MRNA
Moderna, Inc.
$80B 587.1% YTD
ARGX
argenx SE
$55B 4.1% YTD
ONC
BeOne Medicines Ltd.
$43B 25.8% YTD
RVMD
Revolution Medicines, Inc.
$40B 135.6% YTD
RPRX
Royalty Pharma plc
$37B 67.3% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$30B -42.8% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.